Skip to Content
Merck
CN

SML1974

CBLC000 trifluoroacetate

≥95% (HPLC)

Synonym(s):

9H-Carbazole-9-ethanamine, N,N-diethyl-3,6-dinitro- trifluoroacetate, Curaxin CBLC000 trifluoroacetate, N,N-Diethyl-3,6-dinitro-9H-carbazole-9-ethanamine trifluoroacetate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H20N4O4 · C2HF3O2
CAS Number:
324780-02-1
Molecular Weight:
470.40
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C18H20N4O4.C2HF3O2/c1-3-19(4-2)9-10-20-17-7-5-13(21(23)24)11-15(17)16-12-14(22(25)26)6-8-18(16)20;3-2(4,5)1(6)7/h5-8,11-12H,3-4,9-10H2,1-2H3;(H,6,7)

InChI key

VFGJIBCWHYFSHE-UHFFFAOYSA-N

SMILES string

CCN(CC)CCN1C2=C(C=C([N+]([O-])=O)C=C2)C3=C1C=CC([N+]([O-])=O)=C3.FC(F)(C(O)=O)F

assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Related Categories

Biochem/physiol Actions

CBLC000 is a potent inhibitor of FACT (facilitates chromatin transcription) complex that activates p53 and suppresses NF-kB without genotoxicity. CBLC000 induces chromatin trapping of FACT both in vitro and in vivo. CBLC000 exhibits brad anticancer activity. CBLC000 analog clinical candidate CBL0137 decreases self-renewal of GBM stem cells (GSC).
Potent inhibitor of FACT complex that activates p53 and suppresses NF-kB without genotoxicity

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Skin Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000187027
0000187027
0000019388
0000019389
0000014987

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alexander V Gasparian et al.
Science translational medicine, 3(95), 95ra74-95ra74 (2011-08-13)
Effective eradication of cancer requires treatment directed against multiple targets. The p53 and nuclear factor κB (NF-κB) pathways are dysregulated in nearly all tumors, making them attractive targets for therapeutic activation and inhibition, respectively. We have isolated and structurally optimized
Josephine Kam Tai Dermawan et al.
Cancer research, 76(8), 2432-2442 (2016-02-28)
The nearly universal recurrence of glioblastoma (GBM) is driven in part by a treatment-resistant subpopulation of GBM stem cells (GSC). To identify improved therapeutic possibilities, we combined the EGFR/HER2 inhibitor lapatinib with a novel small molecule, CBL0137, which inhibits FACT

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service